Minaris announced the enhancement of its dedicated GMP cell banking suites at its Philadelphia facility, a centralized hub for cell banking and biosafety testing. The upgraded facilities underscore Minaris' commitment to robust GMP infrastructure, regulatory rigor, and a more integrated client experience, enabling Minaris Advanced Testing to offer clients seamless access to expanded manufacturing capabilities. By combining dedicated cell banking suites with characterization testing, daily process updates, and deep technical expertise, Minaris provides a scalable, compliant service that helps clients move their clinical and commercial programs forward with confidence.
The specialized clean rooms feature multiple dedicated suites designed for concurrent cell banking programs, with infrastructure and workflows aligned with EU GMP Annex 1 and global regulatory standards. The suites incorporate controlled personnel and material flow, optimized cleanroom processes and classified environments including ISO 5 (Grade A) critical zones within ISO 7 (Grade B) background cleanrooms. It also brings modernized environmental monitoring and enhanced quality oversight to strengthen contamination control, supported by established tech transfer processes that help programs transition smoothly from development through commercial supply.
"Cell banking is one of the most important steps in biologics and advanced therapy development, and our clients require a partner that delivers quality, predictability, and regulatory assurance from the outset," said Dr. Ilya Koltover, President, Minaris Advanced Testing. "Our goal is to make cell banking simpler by bringing dedicated GMP infrastructure, integrated testing and cell line characterization, regular program updates, and expert teams with decades of experience together under one roof."
The enhancement reinforces Minaris Advanced Testing's integrated model by uniting GMP cell banking with regulatory-aligned characterization and biosafety testing in a single U.S.-based hub. These capabilities, including sterility, mycoplasma, viral safety, and identity testing, simplify the management of Master and Working Cell Banks while providing clients with timely data and coordinated project management.
By centralizing banking and testing in Philadelphia, Minaris Advanced Testing reduces complexity for developers by synchronizing manufacturing, quality, and project management. Each program benefits from dedicated support and transparent communication, including daily manufacturing updates that help clients track progress, plan next steps, and make informed decisions.
"Operational rigor is at the core of our GMP environments," said Dr. Orla Cloak, Chief Executive Officer, Minaris. "These enhanced suites improve efficiency and predictability while maintaining the rigorous standards required for GMP production. With integrated characterization and daily visibility into program progress, we're helping clients reach key milestones on the path to regulatory-ready cell banks."
The enhanced suites further strengthen Minaris Advanced Testing's cell banking offering while demonstrating Minaris' continued commitment to its Philadelphia site as a centralized hub for testing and cell banking. By combining GMP infrastructure, integrated testing services, and long-standing technical expertise, Minaris supports a right-first-time approach that helps reduce risk, keep programs on track, and prepare developers for key clinical and commercial manufacturing milestones.